Yes — Medicare Part D now covers GLP-1 medications for obesity. Here's what changed, which drugs are covered, what you'll pay, and exactly how to get it.
Prior to 2026, Medicare was legally prohibited from covering drugs used primarily for weight loss under Part D. The Inflation Reduction Act and subsequent CMS rule changes finally opened the door. Starting in 2026, Medicare Part D plans are permitted (but not required) to cover GLP-1 receptor agonists for obesity treatment.
| Drug | For Diabetes | For Obesity (2026) | Est. Monthly Copay |
|---|---|---|---|
| Ozempic (semaglutide) | ✅ Covered | ⚠️ Off-label — varies | ~$30–80 |
| Wegovy (semaglutide) | N/A | ✅ Now covered | ~$150–300 |
| Mounjaro (tirzepatide) | ✅ Covered | ⚠️ Off-label — varies | ~$30–80 |
| Zepbound (tirzepatide) | N/A | ✅ Now covered | ~$150–300 |
Call the member services number on the back of your Medicare card or log into your plan's website. Search for "Wegovy," "Zepbound," "semaglutide," or "tirzepatide" in the drug formulary. You need to confirm the drug is covered AND what tier it's on (tier determines your copay).
Schedule an appointment specifically to discuss GLP-1 therapy. Your doctor needs to document your BMI, qualifying conditions, and that you've tried lifestyle modifications. This documentation is required for prior authorization. Bring a list of your weight-related conditions to the appointment.
Almost all Medicare plans require prior authorization for GLP-1 drugs. Your doctor's office submits the PA request on your behalf. The plan reviews it — typically within 72 hours for standard requests, 24 hours for urgent cases. PA is approved or denied based on medical necessity criteria.
Don't give up. Medicare denials can be appealed and are often overturned with additional documentation. Your doctor can write a letter of medical necessity. You have the right to a Level 1 Appeal within 60 days of a denial. Ask your doctor's office if they have an appeal coordinator — many practices handle this routinely.
Once approved, take your prescription to a Medicare-participating pharmacy. For lowest cost, use a preferred pharmacy in your plan's network. Mail-order pharmacies (90-day supply) often have lower copays than retail. Check your Explanation of Benefits to confirm the correct copay was charged.
Estimate what you'll pay based on your Medicare plan type:
Telehealth providers that specialize in GLP-1 prescriptions can help you navigate the prior authorization process and find the most affordable path to your medication.
* Affiliate links — commissions don't affect our content or recommendations.
No. GLP-1 medications are self-administered injectables, which means they're covered under Part D (prescription drug coverage), not Part B (outpatient medical services). Part B covers medications that are typically administered by a healthcare provider in a clinical setting.
Yes — during Medicare's Annual Enrollment Period (October 15 – December 7), you can switch to a Part D plan that covers GLP-1s for obesity. Use the Medicare Plan Finder at medicare.gov to compare plans based on your specific drugs. Changes take effect January 1 of the following year.
Yes — a major change starting in 2025 under the Inflation Reduction Act capped Medicare Part D out-of-pocket drug costs at $2,000 per year. This is excellent news for GLP-1 users since these drugs are expensive. Once you reach $2,000 in out-of-pocket costs, Medicare covers 100% of your drug costs for the rest of the year.
You have the right to appeal. The Medicare appeals process has 5 levels. Level 1 (redetermination) must be requested within 60 days of denial. Your doctor can provide additional documentation of medical necessity. Many initial denials are overturned on appeal with proper documentation. Contact your State Health Insurance Assistance Program (SHIP) for free counseling — find yours at shiphelp.org.
Medicare Part D covers Ozempic for Type 2 diabetes. Medicare generally does not cover GLP-1 drugs for weight loss alone, except Wegovy for patients with existing cardiovascular disease as of 2024.
As of 2024, Medicare Part D covers Wegovy for patients who have existing cardiovascular disease following the SELECT trial results.
Get a formal diagnosis of Type 2 diabetes or obesity-related cardiovascular disease documented by your doctor. Prior authorization is usually required.